DUPUYTREN LITERATURE: ABNORMALITIES IN NORMAL APPEARING TISSUE

These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.

Medline Title Search (Dupuytren + (“Phenotypically normal” or “Clinically unaffected”))

Selected Publications
These studies have demonstrated mechanical, histologic, and biologic abnormalities consistent with Dupuytren in normal-appearing superficial palmar fascia adjacent to areas of visible Dupuytren disease, suggesting regional/systemic, not local/surgical disease:

• Alfonso-Rodríguez Camilo-Andrés, Garzón Ingrid, Garrido-Gómez Juan, Oliveira Ana-Celeste-Ximenes, Martín-Piedra Miguel-Ángel, Scionti Giuseppe, Carriel Víctor, Hernández-Cortés Pedro, Campos Antonio, Alaminos Miguel. (2014). “Identification of Histological Patterns in Clinically Affected and Unaffected Palm Regions in Dupuytren’s Disease.” PLoS ONE 9 (11): e112457. http://dx.plos.org/10.1371/journal.pone.0112457. 
• Azzarone B, Failly-Crepin C, Daya-Grosjean L, Chaponnier C, Gabbiani G. (1983). “Abnormal Behavior of Cultured Fibroblasts from Nodule and Nonaffected Aponeurosis of Dupuytren’s Disease.” Journal of Cellular Physiology 117 (3): 353–61. 
• Bailey AJ, Sims TJ, Gabbiani G, Bazin S, LeLous M. Collagen of Dupuytren’s disease. Clin Sci Mol Med. 1977;53(5):499-502. 
• Bailey AJ. Collagen. In: McFarlane R, McGrouther D, Flint M, editors. Dupuytren’s Disease Biology and Treatment. Hand and Upper Limb Series. 5. Edinburg: Churchill Livingstone; 1990.
• Batta A. Biochemical Diagnosis of Dupuytren’s Disease. East African Scholars Journal of Medical Sciences. 2019;2(3):143-7.
• Bazin S, Le Lous M, et al. (1980). “Biochemistry and Histology of the Connective Tissue of Dupuytren’s Disease Lesions.” Eur J Clin Invest 10 (1): 9–16.
• Brickley-Parsons, D., Glimcher, M. J., Smith, R. J., Albin, R., & Adams, J. P. (1981). Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren’s disease. The Journal of Bone and Joint Surgery. American Volume, 63(5), 787–797. 
• Chen Yunliang, Shi-Wen Xu, et al. (2005). “Matrix Contraction by Dermal Fibroblasts Requires Transforming Growth Factor-Beta/activin-Linked Kinase 5, Heparan Sulfate-Containing Proteoglycans, and MEK/ERK: Insights into Pathological Scarring in Chronic Fibrotic Disease.” The American Journal of Pathology 167 (6): 1699–1711. 
• Delbruck AF, Gurr E. Proteoglycans and glycosaminoglycans. In: McFarlane RM, McGrouther DA, Flint MH, editors. Dupuytren’s Disease Biology and Treatment. Edinburg: Churchill Livingstone; 1990. p. 48-57. 
• Flint MH. (1990). “The Genesis of the Palmar Lesion.” In McFarlane RM, McGrouther DA, Flint MH (Eds): Dupuytren’s Disease Biology and Treatment Churchill Livingstone Edinburg 1990., 136–54. 
• Gelberman RH, Amiel D, Rudolph RM, Vance RM. Dupuytren’s contracture. An electron microscopic, biochemical, and clinical correlative study. J Bone Joint Surg Am. 1980;62(3):425-32. 
• Mayerl C, Del Frari B, Parson W, Boeck G, Piza-Katzer H, Wick G, et al. Characterisation of the inflammatory response in Dupuytren’s disease. J Plast Surg Hand Surg. 2016;50(3):171-9. 
• Menzel EJ NJ, Rietsch A, Millesi H. Connective Tissue Autoantibodies in Dupuytren’s Disease: Associations with HLA DR3. In: Berger A DA, Brenner P, Hinzmann B, editor. Dupuytren’s Disease Pathobiochemistry and Clinical Management. Berlin: Springer-Verlag; 1994. p. 49-61.
• Menzel EJ, Piza H, Zielinski C, Endler AT, Steffen C, Millesi H. Collagen types and anticollagen-antibodies in Dupuytren’s disease. Hand. 1979;11(3):243-8. 
• Millesi H, Reihsner R, Eberhard D, Mallinger R, Hamilton G, Menzel EJ. (1997). “The Mechanical Properties of the Palmar Aponeurosis and Their Significance for the Pathogenesis of Dupuytren’s Contracture.” Journal of Hand Surgery: European Volume 22 (4): 510–17. 
• Pasquali-Ronchetti I, Guerra D, Baccarani-Contri M, Fornieri C, Mori G, Marcuzzi A, et al. A clinical, ultrastructural and immunochemical study of Dupuytren’s disease. J Hand Surg Br. 1993;18(2):262-9. 
• Quaglino D, Bergamini G, Croce A, Boraldi F, Barbieri D, Caroli A, Marcuzzi A, Tiozzo R, Ronchetti IP. (1997). “Cell Behavior and Cell-Matrix Interactions of Human Palmar Aponeurotic Cells in Vitro.” J Cell Physiol 173 (3): 415–22. 
• Riester, S. M., Arsoy, D., Camilleri, E. T., Dudakovic, A., Paradise, C. R., Evans, J. M., … Kakar, S. (2015). RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren’s disease. BMC Medical Genomics, 8(1), 59. https://doi.org/10.1186/s12920-015-0135-8 
• Satish L, Gallo PH, Baratz ME, Johnson S, Kathju S. (2011). “Reversal of TGF-beta1 Stimulation of Alpha-Smooth Muscle Actin and Extracellular Matrix Components by Cyclic AMP in Dupuytren’s-Derived Fibroblasts.” BMC Musculoskelet Disord 12: 113. http://www.ncbi.nlm.nih.gov/pubmed/21612641. 
• Satish L, O’Gorman DB, Johnson S, Raykha C, Gan BS, Wang JH, Kathju S. (2013). “ Increased CCT-Eta Expression Is a Marker of Latent and Active Disease and a Modulator of Fibroblast Contractility in Dupuytren’s Contracture .” Cell Stress Chaperones 18 (4): 397–404. http://www.ncbi.nlm.nih.gov/pubmed/23292503.
• Satish Latha, LaFramboise William A, et al. (2012). “Fibroblasts from Phenotypically Normal Palmar Fascia Exhibit Molecular Profiles Highly Similar to Fibroblasts from Active Disease in Dupuytren’s Contracture.” BMC Medical Genomics. http://www.ncbi.nlm.nih.gov/pubmed/22559715. 
• Tripkovic I, Ogorevc M, Vukovic D, Saraga-Babic S, Mardešić S. Fibrosis-Associated Signaling Molecules Are Differentially Expressed in Palmar Connective Tissues of Patients with Carpal Tunnel Syndrome and Dupuytren’s Disease. Biomedicines. 2022 Dec 11;10(12):3214. doi: 10.3390/biomedicines10123214. Biomedicines. 2022 Dec 11;10(12):3214. doi: 10.3390/biomedicines10123214. 
• Wade R, Igali L, Figus A. Skin involvement in Dupuytren’s disease. J Hand Surg Eur 2016 Jul;41(6):600-8. doi: 10.1177/1753193415601353. 
• Wurster-Hill DH, Brown F, Park JP, Gibson SH. Cytogenetic studies in Dupuytren contracture. Am J Hum Genet. 1988;43(3):285-92. 
• Zhang AY, Fong KD, Pham H, Nacamuli RP, Longaker MT, Chang J. Gene expression analysis of Dupuytren’s disease: the role of TGF-beta2. J Hand Surg Eur Vol. 2008;33(6):783-90. 

Fascia location influences biological activity. Dupuytren affects superficial palmar fascia but never the transverse palmar fascia, and gene expression appears different in these two locations.

One possible explanation is that these two fascial layers are subjected to very different mechanical environments, selectively stimulating Dupuytren mechanobiology in the superficial but not the transverse palmar fascia.

Another is that the superficial palmar fascia is in direct continuity with biologically active subcutaneous fat (Zhang 2008, Shih 2009) but the transverse palmar fascia is not.

Another is that these adjacent interconnected structures have location-specific gene expression regulation mechanisms.

The above studies compared diseased vs. normal-appearing superficial palmar fascia from the same patient. Some studies below found similar gene expression profiles of the transverse palmar fascia and transverse retinacular ligament, suggesting it could be used as control tissue for disease activity.

• Iqbal Syed Amir, Manning Christopher, Syed Farhatullah, Kolluru Venkatesh, Hayton Mike, Watson Stewart, Bayat Ardeshir. (2012). “Identification of Mesenchymal Stem Cells in Perinodular Fat and Skin in Dupuytren’s Disease: A Potential Source of Myofibroblasts with Implications for Pathogenesis and Therapy.” Stem Cells and Development 21 (4): 609–22. http://www.ncbi.nlm.nih.gov/pubmed/21612554.
• Ratajczak-Wielgomas Katarzyna, Gosk Jerzy, Rabczynski Jerzy, Augoff Katarzyna, Podhorska-Okolów Marzenna, Gamian Andrzej, Rutowski Roman. 
•  “Expression of MMP-2, TIMP-2, TGF-ß1, and Decorin in Dupuytren’s Contracture.” Connective Tissue Research 53 (6): 469–77. http://informahealthcare.com/doi/abs/10.3109/03008207.2012.686542. 
• Raykha Christina, Crawford Justin, Gan Bing Siang, Fu Ping, Bach Leon a, O’Gorman David B. (2013). “IGF-II and IGFBP-6 Regulate Cellular Contractility and Proliferation in Dupuytren’s Disease.” Biochimica et Biophysica Acta 1832 (10). The Authors: 1511–19. http://www.ncbi.nlm.nih.gov/pubmed/23623986. 
• Shih Barbara, Wijeratne Dulharie, Armstrong Daniel J, Lindau Tommy, Day Philip, Bayat Ardeshir. (2009). “Identification of Biomarkers in Dupuytren’s Disease by Comparative Analysis of Fibroblasts Versus Tissue Biopsies in Disease-Specific Phenotypes.” Journal of Hand Surgery 34 (1): 124–36. 
• Shih B, Brown JJ, Armstrong DJ, Lindau T, Bayat A. Differential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren’s disease nodule in comparison to control tissue. Hand (N Y). 2009;4(3):294-301. 
• Vi L, Feng L, Zhu RD, Wu Y, Satish L, Gan BS, O’Gorman DB. (2009). “ Periostin Differentially Induces Proliferation, Contraction and Apoptosis of Primary Dupuytren’s Disease and Adjacent Palmar Fascia Cells .” Exp Cell Res 315 (20): 386–3574. http://www.ncbi.nlm.nih.gov/pubmed/19619531. 
• Vi L, Njarlangattil A, Wu Y, Gan BS, O’Gorman DB. (2009). “ Type-1 Collagen Differentially Alters Beta-Catenin Accumulation in Primary Dupuytren’s Disease Cord and Adjacent Palmar Fascia Cells .” BMC Musculoskelet Disord 10: 72. http://www.ncbi.nlm.nih.gov/pubmed/19545383. 
• Zhang AY, Fong KD, Pham H, Nacamuli RP, Longaker MT, Chang J. Gene expression analysis of Dupuytren’s disease: the role of TGF-beta2. J Hand Surg Eur Vol. 2008;33(6):783-90.